King's Ray Biotechnology (01548.HK) announced its interim results, with a loss attributable to shareholders of $129 million, a year-on-year reduction of 29.25%.

Zhitongcaijing APP news, Genscript Biotech (01548.HK) announced its interim results for the six months ending June 30, 2026. The group achieved revenue of 404 million USD, an increase of 27.35% year-on-year; the loss attributable to the company's owners was 129 million USD, narrowing by 29.25% year-on-year; the loss per share was 5.92 cents.